title: Myeloma cells suppress osteoblasts through sclerostin secretion.
abstract: Wingless-type (Wnt) signaling through the secretion of Wnt inhibitors Dickkopf1, soluble frizzled-related protein-2 and -3 has a key role in the decreased osteoblast (OB) activity associated with multiple myeloma (MM) bone disease. We provide evidence that another Wnt antagonist, sclerostin, an osteocyte-expressed negative regulator of bone formation, is expressed by myeloma cells, that is, human myeloma cell lines (HMCLs) and plasma cells (CD138+ cells) obtained from the bone marrow (BM) of a large number of MM patients with bone disease. We demonstrated that BM stromal cells (BMSCs), differentiated into OBs and co-cultured with HMCLs showed, compared with BMSCs alone, reduced expression of major osteoblastic-specific proteins, decreased mineralized nodule formation and attenuated the expression of members of the activator protein 1 transcription factor family (Fra-1, Fra-2 and Jun-D). Moreover, in the same co-culture system, the addition of neutralizing anti-sclerostin antibodies restored OB functions by inducing nuclear accumulation of β-catenin. We further demonstrated that the upregulation of receptor activator of nuclear factor κ-B ligand and the downregulation of osteoprotegerin in OBs were also sclerostin mediated. Our data indicated that sclerostin secretion by myeloma cells contribute to the suppression of bone formation in the osteolytic bone disease associated to MM.
authors: S
authors: S
authors: Colucci
authors: G
authors: G
authors: Brunetti
authors: A
authors: A
authors: Oranger
authors: G
authors: G
authors: Mori
authors: F
authors: F
authors: Sardone
authors: G
authors: G
authors: Specchia
authors: E
authors: E
authors: Rinaldi
authors: P
authors: P
authors: Curci
authors: V
authors: V
authors: Liso
authors: G
authors: G
authors: Passeri
authors: A
authors: A
authors: Zallone
authors: R
authors: R
authors: Rizzi
authors: M
authors: M
authors: Grano